A new Paradigm in the Development and Manufacturing of Antibody-drug Conjugates

A new Paradigm in the Development and Manufacturing of Antibody-drug Conjugates

0 0 hace un año
4 Sesiones 20 Descargas
In this episode of The Onco'Zine Brief, recorded during CPhI World Wide, held October 24 - 27, 2017 in Frankfurt, Germany, Peter Hofland and Sonia Portillo, interview Charlie Johnson, the CEO of ADC Bio.

ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs known as Antibody-drug Conjugates or ADCs.

Antibody-drug Conjugates are a new class of ... Más informaciones

Síguenos en Facebook

Copyright 2019 - Spreaker Inc. a Voxnest Company - Crea un podcast - New York, NY
Help